One of the central unanswered questions in prostate cancer research is the significance of
tyrosine kinase inhibitor (TKI)–induced improvements in 99mTc-methylene diphosphonate …

Background This study explored the efficacy and tolerability of sunitinib, an inhibitor of
tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). Methods …

Introduction Drug development and clinical decision making for patients with metastatic
prostate cancer (PC) have been hindered by a lack of quantitative methods of assessing …

Importance Prostate cancer commonly metastasizes to bone, and bone metastases are
associated with pathologic fractures, pain, and reduced survival. Bone disease is routinely …

5166 Background: Overexpression of VEGF and PDGF has been implicated in prostate
cancer progression and bone metastases. Sunitinib is an oral, multitargeted inhibitor of …

Background In metastatic castration-resistant prostate cancer (mCRPC), assessing
treatment response and bone lesions with technetium-99m is limited by image resolution …

In patients with metastatic castration-resistant prostate cancer, bone is the most common site
for metastases. Because of their osteoblastic character, these lesions are very suitable for …

180 Background: CRPC is frequently associated with the development of osseous
metastases. While imaging allows treatment response determination in soft tissue …

5006 Background: Quantitative measures of metastatic bone disease are needed in men
with mCRPC. We recently demonstrated the validity/reproducibility of a computational …

5157 Background: Sunitinib malate is a multitargeted tyrosine kinase inhibitor approved
multinationally for renal cell carcinoma and gastrointestinal stromal tumors. Effective options …